Jump to main content
Jump to site search

Issue 32, 2014
Previous Article Next Article

Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors

Author affiliations

Abstract

In the JAK/STAT pathway, sustainable activation of JAK with the capabilities of regulating cell growth and apoptosis can produce abnormal proliferation in tumor cells. A series of novel metronidazole derivatives containing the 1,4-benzodioxan moiety as potential inhibitors targeting JAK have been designed, synthesized and their biological activities were also evaluated. Among all synthesized compounds, compound 4t possessed the most potent antitumor activity against A549, Hela, HepG-2 and U251 in vitro, with IC50 values of 65, 21, 16 and 44 nM, respectively, which has been proved by the result of a flow cytometry (FCM) assay. Docking simulations demonstrated that compound 4t could bind tightly with the crystal structure of the JAK3 active site and act as a potential JAK3 inhibitor.

Graphical abstract: Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors

Back to tab navigation

Publication details

The article was received on 20 Feb 2014, accepted on 26 Mar 2014 and first published on 26 Mar 2014


Article type: Paper
DOI: 10.1039/C4RA01444H
Citation: RSC Adv., 2014,4, 16694-16704
  •   Request permissions

    Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors

    Y. Sang, Y. Duan, H. Qiu, P. Wang, J. A. Makawana, Z. Wang, H. Zhu and Z. He, RSC Adv., 2014, 4, 16694
    DOI: 10.1039/C4RA01444H

Search articles by author

Spotlight

Advertisements